Ke Xu1, John H Krystal1, Yuping Ning2, Da Chun Chen3, Hongbo He2, Daping Wang2, Xiaoyin Ke2, Xifan Zhang4, Yi Ding2, Yuping Liu2, Ralitza Gueorguieva5, Zuoheng Wang6, Diana Limoncelli7, Robert H Pietrzak1, Ismene L Petrakis1, Xiangyang Zhang3, Ni Fan8. 1. Department of Psychiatry, Yale School of Medicine, 300 George St, New Haven, CT, USA; United States Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, CT, USA. 2. Guangzhou Brain Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. 3. Biological Psychiatry Center, Beijing Hui-Long-Guan Hospital, Peking University, Beijing 100096, China. 4. Guangzhou Baiyun Mental Health Hospital, China. 5. Department of Psychiatry, Yale School of Medicine, 300 George St, New Haven, CT, USA; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA. 6. Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA. 7. United States Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, CT, USA. 8. Guangzhou Brain Hospital, The Affiliated Brain Hospital of Guangzhou Medical University, 36 Mingxin Road, Liwan District, Guangzhou, Guangdong Province 510370, China. Electronic address: fanni2005@126.com.
Abstract
OBJECTIVE: Studies of the effects of the N-methyl-d-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). METHOD: We conducted exploratory factor analysis for the PANSS from four groups: 135 healthy subject administrated ketamine or saline, 187 inpatients of ketamine abuse; 154 inpatients of early course schizophrenia and 522 inpatients of chronic schizophrenia. Principal component factor analyses were conducted to identify the factor structure of the PANSS. RESULTS: Factor analysis yielded five factors for each group: positive, negative, cognitive, depressed, excitement or dissociation symptoms. The symptom dimensions in two schizophrenia groups were consistent with the established five-factor model (Wallwork et al., 2012). The factor structures across four groups were similar, with 19 of 30 symptoms loading on the same factor in at least 3 of 4 groups. The factors in the chronic ketamine group were more similar to the factors in the two schizophrenia groups rather than to the factors in the acute ketamine group. Symptom severities were significantly different across the groups (Kruskal-Wallis χ(2)(4) = 540.6, p < 0.0001). Symptoms in the two ketamine groups were milder than in the two schizophrenia groups (Cohen's d = 0.7). CONCLUSION: Our results provide the evidence of similarity in symptom dimensions between ketamine psychosis and schizophrenia psychosis. The interpretations should be cautious because of potential confounding factors.
OBJECTIVE: Studies of the effects of the N-methyl-d-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophreniapatients (early and chronic stages). METHOD: We conducted exploratory factor analysis for the PANSS from four groups: 135 healthy subject administrated ketamine or saline, 187 inpatients of ketamine abuse; 154 inpatients of early course schizophrenia and 522 inpatients of chronic schizophrenia. Principal component factor analyses were conducted to identify the factor structure of the PANSS. RESULTS: Factor analysis yielded five factors for each group: positive, negative, cognitive, depressed, excitement or dissociation symptoms. The symptom dimensions in two schizophrenia groups were consistent with the established five-factor model (Wallwork et al., 2012). The factor structures across four groups were similar, with 19 of 30 symptoms loading on the same factor in at least 3 of 4 groups. The factors in the chronic ketamine group were more similar to the factors in the two schizophrenia groups rather than to the factors in the acute ketamine group. Symptom severities were significantly different across the groups (Kruskal-Wallis χ(2)(4) = 540.6, p < 0.0001). Symptoms in the two ketamine groups were milder than in the two schizophrenia groups (Cohen's d = 0.7). CONCLUSION: Our results provide the evidence of similarity in symptom dimensions between ketaminepsychosis and schizophrenia psychosis. The interpretations should be cautious because of potential confounding factors.
Authors: John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman Journal: Psychopharmacology (Berl) Date: 2003-09-02 Impact factor: 4.530
Authors: Naomi R Driesen; Gregory McCarthy; Zubin Bhagwagar; Michael H Bloch; Vincent D Calhoun; Deepak C D'Souza; Ralitza Gueorguieva; George He; Hoi-Chung Leung; Ramachandran Ramani; Alan Anticevic; Raymond F Suckow; Peter T Morgan; John H Krystal Journal: Neuropsychopharmacology Date: 2013-07-16 Impact factor: 7.853
Authors: D Dickerson; B Pittman; E Ralevski; A Perrino; D Limoncelli; J Edgecombe; G Acampora; J H Krystal; I Petrakis Journal: J Psychopharmacol Date: 2008-11-21 Impact factor: 4.153
Authors: Alan Anticevic; Michael W Cole; Grega Repovs; Aleksandar Savic; Naomi R Driesen; Genevieve Yang; Youngsun T Cho; John D Murray; David C Glahn; Xiao-Jing Wang; John H Krystal Journal: Front Psychiatry Date: 2013-12-24 Impact factor: 4.157
Authors: James M Stone; Fiona Pepper; Johnson Fam; Hannah Furby; Emer Hughes; Celia Morgan; Oliver D Howes Journal: Psychopharmacology (Berl) Date: 2013-11-22 Impact factor: 4.530
Authors: Milan Scheidegger; Martin Walter; Mick Lehmann; Coraline Metzger; Simone Grimm; Heinz Boeker; Peter Boesiger; Anke Henning; Erich Seifritz Journal: PLoS One Date: 2012-09-24 Impact factor: 3.240
Authors: Steven J Pennybaker; David A Luckenbaugh; Lawrence T Park; Craig A Marquardt; Carlos A Zarate Journal: Biol Psychiatry Date: 2017-01-22 Impact factor: 13.382
Authors: Stephanie Thiebes; Gregor Leicht; Stjepan Curic; Saskia Steinmann; Nenad Polomac; Christina Andreou; Iris Eichler; Lars Eichler; Christian Zöllner; Jürgen Gallinat; Ileana Hanganu-Opatz; Christoph Mulert Journal: J Psychiatry Neurosci Date: 2017-06 Impact factor: 6.186
Authors: Raissa Nobrega; Kathy A Sheehy; Caroline Lippold; Amy L Rice; Julia C Finkel; Zenaide M N Quezado Journal: Pediatr Res Date: 2017-09-13 Impact factor: 3.756